Poseida Therapeutics: Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

Poseida Therapeutics
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting
P-BCMA-101 showed a 100% ORR with patients achieving rapid and deep responses with no CRS or neurotoxicity observed at the planned Phase 2 dose
December 3, 2018